title: Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy.
abstract: Neuroendocrine tumors have a propensity to metastasize to the heart, although the reason for this remains unknown. A review of 251 neuroendocrine tumor patients treated with Lu DOTATATE peptide receptor radionuclide therapy or I-MIBG therapy at our institution since 2003 revealed 2 patients with cardiac metastases (incidence, 0.8%), one treated with Lu DOTATATE and one with I-MIBG. We present the imaging findings of these 2 patients, as well as their management and responses to therapy.
authors.affiliation: From the *Department of Diagnostic Imaging, Cross Cancer Institute, Edmonton, Alberta; and †Department of Nuclear Medicine, London Health Sciences Centre, University Hospital, London, Ontario, Canada.
authors.forename: William
authors.initials: W
authors.lastname: Makis
authors.forename: Karey
authors.initials: K
authors.lastname: McCann
authors.forename: Mark
authors.initials: M
authors.lastname: Bryanton
authors.forename: Alexander J B
authors.initials: AJ
authors.lastname: McEwan
mesh_terms: D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D000368:Aged; D005260:Female; D006338:Heart Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000473:pathology / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D013953:Thymus Neoplasms / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine; C447941:lutetium Lu 177 dotatate; D015282:Octreotide